Short answer
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $67M (up 15.2% year over year) with net income of −$91M.
Q3 2025 key financials · XBRL
- Revenue
- $67M
- +15.2% YoY · +12.5% QoQ
- Net income
- −$91M
- −9.2% YoY · +18.3% QoQ
- Operating margin
- -140.7%
- EPS (diluted)
- −$0.25
- +7.4% YoY · +24.2% QoQ
Source: XBRL data from the IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Q3 2025 10-Q on SEC EDGAR. USD.
IOVANCE BIOTHERAPEUTICS, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Strategic restructuring with 19% workforce reduction completed Sept 2025 to cut costs and extend cash runway
- Updated financial risk: Raised $350M ATM equity facility with Jefferies in Aug 2025 to support operations and product commercialization
- Regulatory risk: Ongoing assessment of 2025 One Big Beautiful Bill Act tax law changes impacting consolidated financial statements
- Competitive risk: Intense competition from biotech/pharma and nonprofits may limit market acceptance and revenues for products
- Financial risk: Cash of $306.8M as of Sept 30, 2025 with net loss $319.1M over nine months increases need for future capital
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other IOVANCE BIOTHERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.